VINCOV-19, a novel therapeutic antibody engineered product has received approval from the Drugs Controller General of India (DGCI) for its clinical trials. The product is the collaborative effort of the University of Hyderabad (UoH), CSIR-Centre for Cellular and Molecular Biology (CCMB), Hyderabad, and VINS Bioproducts Limited.
